Literature DB >> 7876625

Phase-variable expression of the 145-kDa surface protein of Brazilian purpuric fever case-clone strains of Haemophilus influenzae biogroup aegyptius.

L G Rubin1.   

Abstract

Clonally related strains of Haemophilus influenzae biogroup aegyptius have recently been associated with Brazilian purpuric fever (BPF). Antibodies to a 145-kDa minor outer membrane protein (P145) are bactericidal and protect against experimental bacteremia. To determine if P145 is conserved among case-clone strains, case-clone strains were screened for P145 expression. Assays of a large number of colonies of each strain using colony immunoblot revealed colonies reactive with anti-P145 sera in all 17 case-clone strains. P145 was expressed at a low frequency (0.08%-2.2% of colonies) in 14 strains and at a high frequency (> 98%) in 3 strains. Expression of P145 by reactive colonies was confirmed by SDS-PAGE. Also, anti-P145-nonreactive variant colonies of P145-expressing strains were detected in 0.4%-1.5% of colonies. These findings indicate P145 is conserved among BPF case-clone strains and is subject to phase-variable expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876625     DOI: 10.1093/infdis/171.3.713

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

Review 1.  Emergence and disappearance of a virulent clone of Haemophilus influenzae biogroup aegyptius, cause of Brazilian purpuric fever.

Authors:  Lee H Harrison; Vera Simonsen; Eliseu A Waldman
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 2.  Molecular population genetic analysis of emerged bacterial pathogens: selected insights.

Authors:  J M Musser
Journal:  Emerg Infect Dis       Date:  1996 Jan-Mar       Impact factor: 6.883

3.  Role of the 145-kilodalton surface protein in virulence of the Brazilian purpuric fever clone of Haemophilus influenzae biogroup aegyptius for infant rats.

Authors:  L G Rubin
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.